Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system
Authors' conclusion
Although nearly one-half of all patients in a large health care system were AOM-eligible by guidelines and regulatory labeling, only 1% of those who were eligible were prescribed AOMs.
Study context
- Population
- Adults in the Mass General Brigham health care system (Boston, Massachusetts), 2018 to 2022; Antiobesity medication (AOM) eligibility: BMI ≥ 30 kg/m² or BMI 27–29.9 kg/m² with ≥1 ORC1,110,251 AOM-eligible
- Participants
- 2,469,474 adults
- Outcome
- Prevalence of prescriptions for AOMs approved for long-term weight management among AOM-eligible adults
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
AOM prescription among AOM-eligible patients
AOM-eligible adults
1,110,251
45.0%
AOM prescription among eligible patients
15,214
1.4%
Observational data: associations, not effects.
Further findings
BMI ≥ 30 kg/m² among AOM-eligible
- BMI ≥ 30 kg/m² among eligible
- 69.4%
- BMI ≥ 30 kg/m² in overall cohort
- 31.2%
Obesity-related conditions (ORCs)
- Musculoskeletal disorders (most common ORC)
- 54%
- ≥2 ORCs
- 62%
AOMs prescribed
- Liraglutide 3.0 mg, share of all AOMs
- 58%
- Semaglutide 2.4 mg, share of all AOMs
- 34%
Original publication
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system. Obesity (Silver Spring). Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →